Publications by authors named "A Soledad Firpo"
To contribute to the study of the disease, data were recorded from all hospitalized patients in the Clinical Medicine room of Hospital Municipal Dr. Raúl Caccavo, Coronel Suárez, Buenos Aires province, diagnosed with COVID-19 in the first year of the pandemia (March 2020 to March 2021), the only health institution where patients were hospitalized in our city. A descriptive and retrospective transversal cut study was carried out with 178 patients (average age: 61 years old, range: 9 months -96 years), 90% of them hospitalized for a respiratory cause.
View Article and Find Full Text PDFThe objective was to describe the results of a surveillance strategy based on the use of SARS-CoV-2 rapid antigen detection tests. A retrospective cohort study was held between December 2020 and March 2021, which included suspected cases of COVID-19 evaluated by rapid antigen tests at a public hospital, with confirmatory molecular tests in negative cases. Positive cases and their close contacts were followed up by telephone.
View Article and Find Full Text PDFSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated clinical syndrome COVID-19 are causing overwhelming morbidity and mortality around the globe and disproportionately affected New York City between March and May 2020. Here, we report on the first 100 COVID-19-positive autopsies performed at the Mount Sinai Hospital in New York City. Autopsies revealed large pulmonary emboli in six cases.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to analyze clinical characteristics and outcomes of hospitalized COVID-19 patients, comparing those who died in the hospital to those who were discharged alive.
- Data was collected from five hospitals in the Mount Sinai Health System for patients confirmed with COVID-19 between February and April 2020, focusing on demographics, clinical features, and mortality rates.
- Results showed that nearly half of the 2199 hospitalized patients were discharged, with a 29% overall mortality rate, higher rates of pre-existing conditions and lower lymphocyte percentages observed in patients who died compared to those who recovered.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with millions infected and more than 1 million fatalities. Questions regarding the robustness, functionality, and longevity of the antibody response to the virus remain unanswered. Here, on the basis of a dataset of 30,082 individuals screened at Mount Sinai Health System in New York City, we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust immunoglobulin G antibody responses against the viral spike protein.
View Article and Find Full Text PDF